Mark Perry
Direktor/Vorstandsmitglied bei NVIDIA CORPORATION
Vermögen: 114 Mio $ am 30.04.2024
Profil
Mark L.
Perry currently works at NVIDIA Corp., as Lead Independent Director from 2018, The State Bar of California, as Member, and The Association of Bioscience Financial Officers, as Member.
Mr. Perry also formerly worked at Aerovance, Inc., as President, Chief Executive Officer & Director from 2007 to 2011, Pathway Therapeutics, Inc., as Chairman, Nuvelo, Inc., as Director from 2003 to 2009, IntraBiotics Pharmaceuticals, Inc., as Director, MyoKardia, Inc., as Lead Independent Director from 2014 to 2020, Global Blood Therapeutics, Inc., as Independent Director, Gilead Sciences, Inc., as CFO, Executive VP-Operations & General Counsel from 1994 to 2004, Cooley LLP, as Partner from 1987 to 1994, and California State Bar Association, as Member.
Mr. Perry received his undergraduate degree from the University of California, Berkeley and graduate degree in 1980 from the University of California, Davis.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
NVIDIA CORPORATION
0,01% | 02.04.2024 | 131 612 ( 0,01% ) | 114 Mio $ | 30.04.2024 |
Aktive Positionen von Mark Perry
| Unternehmen | Position | Beginn |
|---|---|---|
| NVIDIA CORPORATION | Direktor/Vorstandsmitglied | 01.05.2005 |
The State Bar of California
 The State Bar of California Miscellaneous Commercial ServicesCommercial Services The State Bar of California operates as an official attorney licensing agency. The non-profit company is based in San Francisco, CA. Elizabeth Rindskopf Parker has been the CEO of the company since 2015. | Corporate Officer/Principal | - |
The Association of Bioscience Financial Officers
 The Association of Bioscience Financial Officers Miscellaneous Commercial ServicesCommercial Services The Association of Bioscience Financial Officers operates as a national networking group for biotechnology, med tech and bioscience financial officers. The company was founded in 1988 and is headquartered in Menlo Park, CA. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Mark Perry
| Unternehmen | Position | Ende |
|---|---|---|
| GLOBAL BLOOD THERAPEUTICS, INC. | Vorsitzender | 05.10.2022 |
| MYOKARDIA, INC. | Direktor/Vorstandsmitglied | 17.11.2020 |
Aerovance, Inc.
 Aerovance, Inc. Medical DistributorsDistribution Services Aerovance, Inc. develops drugs for respiratory and inflammatory diseases. The company was founded by Jeffrey Howard Tepper and Wolf-Dieter Busse in July 29, 2004 and is headquartered in Berkeley, CA. | Vorstandsvorsitzender | 01.01.2011 |
| Nuvelo, Inc. | Direktor/Vorstandsmitglied | 28.01.2009 |
IntraBiotics Pharmaceuticals, Inc.
 IntraBiotics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology IntraBiotics, a developer of antibiotics and antifungals is focused on one drug candidate, iseganan hydrochloride oral solution, which would be used for the prevention of ventilator-associated pneumonia and to help cystic fibrosis patients fight respiratory infections. | Direktor/Vorstandsmitglied | 01.12.2005 |
Ausbildung von Mark Perry
| University of California, Davis | Graduate Degree |
| University of California, Berkeley | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| NVIDIA CORPORATION | Electronic Technology |
| GILEAD SCIENCES, INC. | Health Technology |
| Private Unternehmen | 10 |
|---|---|
| Nuvelo, Inc. | Health Technology |
IntraBiotics Pharmaceuticals, Inc.
IntraBiotics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology IntraBiotics, a developer of antibiotics and antifungals is focused on one drug candidate, iseganan hydrochloride oral solution, which would be used for the prevention of ventilator-associated pneumonia and to help cystic fibrosis patients fight respiratory infections. | Health Technology |
Aerovance, Inc.
Aerovance, Inc. Medical DistributorsDistribution Services Aerovance, Inc. develops drugs for respiratory and inflammatory diseases. The company was founded by Jeffrey Howard Tepper and Wolf-Dieter Busse in July 29, 2004 and is headquartered in Berkeley, CA. | Distribution Services |
The State Bar of California
The State Bar of California Miscellaneous Commercial ServicesCommercial Services The State Bar of California operates as an official attorney licensing agency. The non-profit company is based in San Francisco, CA. Elizabeth Rindskopf Parker has been the CEO of the company since 2015. | Commercial Services |
Cooley LLP
 Cooley LLP Miscellaneous Commercial ServicesCommercial Services Cooley LLP engages in the provision of legal services. It offers strategic litigation and business transaction services and is a representative of private and public companies, financial institutions, venture capital firms and nonprofit organizations. Its practices include commercial litigation; patent counseling and prosecution; employment and labor; asset recovery; and estate planning and personal representation. The company was founded in 1920 and is headquartered in New York, NY. | Commercial Services |
Pathway Therapeutics, Inc.
 Pathway Therapeutics, Inc. BiotechnologyHealth Technology Pathway Therapeutics, Inc. operates as a clinical stage, privately held, pharmaceutical company developing differentiated and best in class isoform specific PI3-kinase (PI3K) inhibitors for oncology, inflammatory and respiratory diseases. Its lead product include PWT33597, demonstrates excellent in vitro selectivity for its targets, with negligible activity against other protein kinases and other pharmacologically relevant targets at biologically active concentrations. The firm’s other product include PWT143, which has shown outstanding efficacy in in vivo models and has an excellent DMPK and safety profile suitable for advancement in multiple indications. The company was founded in 2010 by William A. Denny and Peter Robin Shepherd and is headquartered in San Francisco, CA. | Health Technology |
MyoKardia, Inc.
 MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |
The Association of Bioscience Financial Officers
The Association of Bioscience Financial Officers Miscellaneous Commercial ServicesCommercial Services The Association of Bioscience Financial Officers operates as a national networking group for biotechnology, med tech and bioscience financial officers. The company was founded in 1988 and is headquartered in Menlo Park, CA. | Commercial Services |
Global Blood Therapeutics, Inc.
 Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA. | Health Technology |
| California State Bar Association |
